Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Colorectal Cancer
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
Colorectal cancer is one of the most common malignant tumors, accounting for approximately 10% of new cancer cases and cancer-related deaths worldwide each year.
- Trial name
- NCT06698757
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Yugui Lian
Rectal Cancer
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
- Trial name
- BRANCH (NCT01481545)
- Testing
- Radiation therapy, Oxaliplatin, Raltitrexed
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute, Naples
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
The goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs).
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07397442
- Testing
- Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Beijing Friendship Hospital
Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with…
- Trial name
- NCT07277842
- Testing
- Serplulimab, FOLFOXIRI chemotherapy, CAPOX chemotherapy
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
- Trial name
- NCT04468607
- Testing
- BLYG8824A
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy
For locally advanced rectal cancer, the initial goal of neoadjuvant chemoradiotherapy is to reduce local recurrence, but the pathologic complete response (PCR) rate is low, and distant metastasis becomes the main treatment…
- Trial name
- NCT06099951
- Testing
- Serplulimab + FOLFOXIRI, Radiation therapy
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to evaluate the efficacy and safety of short-course radiotherapy followed by AK112 in combination with CAPOX as neoadjuvant therapy in patients with locally advanced rectal cancer
- Trial name
- NCT06802666
- Testing
- short-course radiotherapy, Ivonescimab, capecitabine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Rectal Cancer
Minimal Invasive Strategies for Good and Complete Response to Chemoradiation in Rectal Cancer
The high proportion of complete and good responders with modern chemoradiation and the improvement in magnetic resonance (MR)-imaging techniques have stimulated a renewed interest to the question whether in patients with complete…
- Trial name
- NCT00939666
- Testing
- Wait&see or TEM with intensive follow-up
- Where
- 2 sites in Netherlands
- Volunteers
- 28 people
- Sponsor
- Maastricht University Medical Center
Colorectal Cancer
A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents
Fruquintinib is already the standard third-line treatment for metastatic colorectal cancer, but the efficacy of fruquintinib in neoadjuvant and conversion therapy for locally advanced/advanced colorectal cancer has not yet been…
- Trial name
- NCT06470178
- Testing
- corhot1: chemotherapy combined with fruquintinib, corhot2: chemotherapy combined with fruquintinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Wuhan University
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Rectal Cancer, Radiotherapy
A Prospective Phase II Randomized Clinical Trial of Preoperative Chemotherapy Combined With Short-course Radiotherapy Versus Conventional Neo-adjuvant Therapy for Locally Advanced Rectal Cancer Implemented by MDT
The study is designed to analyze the pathological tumor response on locally advanced rectal cancer after preoperative treatment with neo-adjuvant therapy regimen or with chemotherapy combined with short-course radiotherapy in a…
- Trial name
- NCT02941562
- Testing
- Short-course radiotherapy, FOLFOX4 chemotherapy,preoperative, Radiotherapy of neo-adjuvant therapy
- Volunteers
- 150 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Locally Advanced Resectable Rectal Cancer
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
- Trial name
- NCT07454720
- Testing
- Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 165 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Colorectal Cancer
Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to evaluate the clinical efficacy and safety of anlotinib in combination with penpulimab and conventional chemoradiotherapy for the neoadjuvant treatment of locally advanced rectal cancer
- Trial name
- LARC-nCR01 (NCT06853769)
- Testing
- Anlotinib hydrochloride,Penpulimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer
The current standard treatment for locally advanced rectal cancer is still fluorouracil-based neoadjuvant radiotherapy and chemotherapy followed by TME surgery, followed by adjuvant chemotherapy.
- Trial name
- FANTASTIC (NCT04338191)
- Testing
- mFOLFOXIRI adjuvant chemotherapy, mFOLFOX6 adjuvant chemotherapy
- Where
- China
- Volunteers
- 638 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer
This is a single arm phase II trial with combined celecoxib, tegafur-uracil, folinate and preoperative radiotherapy for patients with locally advanced rectal cancer.
- Trial name
- NCT00931203
- Testing
- Celecoxib
- Where
- Taiwan
- Volunteers
- 55 people
- Sponsor
- National Health Research Institutes, Taiwan
Rectal Cancer Stage III
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
To explore whether the application of irinotecan under the guidance of UGT1A1 gene in neoadjuvant chemotherapy and radiotherapy for locally advanced rectal cancer could improve the clinical efficacy in the real world.
- Trial name
- NCT05148767
- Testing
- Neoadjuvant chemoradiotherapy based on irinotecan
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancers
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial
To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer
- Trial name
- NCT07622771
- Testing
- Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX, Adalimumab+NALIRIFOX→Long course chemoradiotherapy →Adalimumab+NALIRIFOX
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
Immunoscore has been reported to be superior to microsatellite instability staging in predicting the disease-specific recurrence and survival for patients with colorectal cancer.
- Trial name
- SILAR (NCT05450029)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Yanhong Deng
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer